Breast Cancer News and Research

Latest Breast Cancer News and Research

Risk of radiation-induced breast cancer from mammographic screening slight in comparison to benefits

The risk of radiation-induced breast cancer from mammography screening is slight in comparison to the benefit of expected lives saved, according to a new study appearing online and in the January issue of the journal Radiology.

17 Nov 2010

Targeted therapies could treat a broad range of cancers: Research

Targeted cancer therapies such as trastuzumab (Herceptin), gefitinib (Iressa) and erlotinib (Tarceva) could be used to treat a wider range of cancers than previously thought, according to new research presented today (Wednesday) at the 22nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Berlin.

17 Nov 2010

New OncoMap technique can detect point mutation in ovarian cancer

Researchers have shown that point mutations mis-spellings in a single letter of genetic code that drive the onset and growth of cancer cells can be detected successfully in advanced ovarian cancer using a technique called OncoMap. The finding opens the way for personalised medicine in which every patient could have their tumour screened, specific mutations identified, and the appropriate drug chosen to target the mutation and halt the growth of their cancer.

17 Nov 2010

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today presented data from preclinical studies of three investigational messenger RNA (mRNA) antagonists. These antagonists are based on the locked nucleic acid (LNA) technology platform targets licensed from Santaris Pharma A/S.

17 Nov 2010

Study: EGFR inhibtion may help treat triple negative breast cancer

Scientists believe they may have found a new target for treating triple negative breast cancer - one of the more difficult breast cancers to treat successfully and for which there is no targeted therapy at present.

17 Nov 2010

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine (Xeloda®) in patients with certain advanced solid tumors.

17 Nov 2010

Verastem closes $16 million Series A financing

Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat cancer by targeting cancer stem cells, today announced the closing of a $16 million Series A financing. Founding investor, Longwood Founders Fund, was joined by Bessemer Venture Partners, Cardinal Partners, and MPM Capital.

16 Nov 2010

Risk reduction of 20 ailments with regular exercise: Review

In a review article researchers have concluded that regular exercise cuts the risk of more than 20 illnesses. Some of these include colon cancer, heart disease, diabetes, osteoporosis and stroke said the study published in the International Journal of Clinical Practice.

16 Nov 2010

Urgent need for bowel cancer screening funding

Bowel Cancer Foundation chairman, Graham Newstead feeling frustrated at the federal government’s indecision on bowel cancer screening funds has expressed his dismay. He suggested that the government should ensure the future funding for the screening test that has saved an estimated 11,000 lives since screening was introduced in 2006.

16 Nov 2010

Merrion prepares Phase III study for Orazol in breast cancer treatment

After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA's abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer.

16 Nov 2010

Canadian government announces new research initiative on childhood obesity

The Honourable Leona Aglukkaq, Minister of Health, today announced new initiatives for research on physical activity and childhood obesity through the Canadian Institutes of Health Research (CIHR).

16 Nov 2010

FDA approves Halaven therapy for metastatic late-stage breast cancer

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate) to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease.

16 Nov 2010

RBC boosting drugs may undermine breast cancer treatment with Herceptin

Red-blood-cell-boosting drugs used to treat anemia may undermine breast cancer treatment with Herceptin, a targeted therapy that blocks the cancer-promoting HER2 protein, researchers from The University of Texas MD Anderson Cancer Center report in the Nov. 16 edition of Cancer Cell.

16 Nov 2010

First Edition: November 15, 2010

According to today's headlines, Republicans are spoiling for a health care fight and doctors are bracing from scheduled Medicare cuts.

15 Nov 2010

New AccuDetect software reduces false-positive rates during mammography screening

Parascript, LLC, the image analysis and pattern recognition technology provider, today announced the release of AccuDetect 4.0, the next generation of its computer-aided detection (CAD) software with significant performance improvements and a greater potential for lowering false-positive rates when detecting suspicious lesions on mammograms, compared to the previous version of the product.

15 Nov 2010

New study finds PEM reduces unnecessary breast biopsies

The Radiology journal released new data from an NIH-sponsored, multi-site study of hundreds of women with newly diagnosed breast cancer that shows Positron Emission Mammography (PEM) may reduce unnecessary breast biopsies. The study found that PEM was significantly more precise at identifying benign and cancerous lesions, in what scientists call "Positive Predictive Value" or "PPV," therefore reducing the number of unnecessary biopsies.

15 Nov 2010

DS Waters extends partnership with Susan G. Komen for the Cure

DS Waters of America, Inc., a leader in home and office bottled water, water filtration and office coffee delivery service, today announced it has extended its current partnership with Susan G. Komen for the Cure until January 30, 2016, extending the parties' prior commitment by an additional five years. The modified agreement also adds water filtration to the list of products associated with Komen for the Cure.

12 Nov 2010

SU2C to receive second CLIO Healthcare Award

The CLIO Healthcare Awards will present its second annual honorary award, to Stand Up To Cancer (SU2C), on November 12th, 2010. This dedicated award celebrates an organization or individual for excellence in healthcare communications and for contributing to the improvement of public health.

12 Nov 2010

33rd CTRC-AACR Symposium to feature breast cancer research

The 33rd CTRC-AACR San Antonio Breast Cancer Symposium will feature the latest findings in prevention, epidemiological, laboratory, translational and clinical breast cancer research. This year's symposium will highlight new therapies in the pipeline, new approaches with existing agents and emerging biology that will affect the quest for personalized medicine.

12 Nov 2010

NCI awards $11.5 million to Fred Hutchinson Center for breast cancer research

The National Cancer Institute has awarded $11.5 million to Fred Hutchinson Cancer Research Center to lead a five-year, Seattle-based breast cancer research consortium. The goal of the endeavor is to positively impact breast cancer prevention, detection, treatment and care of women who have or are at risk for the disease.

11 Nov 2010